The initial immune reaction to a new tumor antigen is always stimulatory and probably necessary for the tumor's growth.
All nascent neoplasms probably elicit at least a weak immune reaction. However, the initial effect of the weak immune reaction on a nascent tumor is always stimulatory rather than inhibitory to tumor growth, assuming only that exposure to the tumor antigens did not antedate the initiation of the neoplasm (as may occur in some virally induced tumors). This conclusion derives from the observation that the relationship between the magnitude of an adaptive immune reaction and tumor growth is not linear but varies such that while large quantities of antitumor immune reactants tend to inhibit tumor growth, smaller quantities of the same reactants are, for unknown reasons, stimulatory. Any immune reaction must presumably be small before it can become large; hence the initial reaction to the first presentation of a tumor antigen must always be small and in the stimulatory portion of this nonlinear relationship. In mouse-skin carcinogenesis experiments it was found that premalignant papillomas were variously immunogenic, but that the carcinomas that arose in them were, presumably because of induced immune tolerance, nonimmunogenic in the animal of origin.
Prehn
Richmond T
RT
Department of Pathology, School of Medicine, University of Washington, 5433 South Hudson St, Seattle, WA 90118, USA. prehn@u.washington.edu
D056704:Adaptive Immunity; D000818:Animals; D000917:Antibody Formation; D017951:Antigen Presentation; D000951:Antigens, Neoplasm / Q000276:immunology*; D002471:Cell Transformation, Neoplastic; D018450:Disease Progression; D006801:Humans; D007157:Immunologic Surveillance; D051379:Mice; D010212:Papilloma / Q000276:immunology* / Q000473:pathology; D012878:Skin Neoplasms / Q000276:immunology* / Q000473:pathology
D000951:Antigens, Neoplasm
J Natl Cancer Inst. 1971 Sep;47(3):653-65
4945592
Prog Exp Tumor Res. 1970;13:1-27
4921480
Cancer Metastasis Rev. 1984;3(1):53-74
6370420
Immunol Rev. 2008 Apr;222:341-56
18364013
Annu Rev Med. 1988;39:63-73
3285791
Int J Immunopharmacol. 1984;6(4):299-305
6480195
Adv Cancer Res. 1975;22:261-422
766581
J Invest Dermatol. 1971 Feb;56(2):102-12
4933758
Clin Cancer Res. 1997 Jan;3(1):51-5
9815537
Br J Cancer. 1976 Mar;33(3):241-59
773395
Science. 1972 Apr 14;176(4031):170-1
5014438
Br J Cancer. 1981 Nov;44(5):753-6
6459113
J Natl Cancer Inst. 1993 Mar 17;85(6):457-64
8445673
Br J Cancer. 2009 Aug 4;101(3):379-80
19638985
Hum Exp Toxicol. 2002 Feb;21(2):91-7
12102503
JAMA. 2006 Dec 20;296(23):2823-31
17179459
Int J Cancer. 1977 May 15;19(5):670-2
863545
Br J Cancer. 2009 Aug 4;101(3):381-6
19638986
Eur Urol. 2009 Sep;56(3):512-8
19559518
Cancer Res. 1960 Dec;20:1561-72
13756652
Int J Cancer. 2003 Jun 10;105(2):249-54
12673687
Lancet. 1995 Sep 23;346(8978):796-8
7674744
AIDS Patient Care STDS. 2005 Oct;19(10):635-44
16232048
Cancer Res. 1969 Dec;29(12):2374-80
5369684